Navigation Links
Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the Treatment of Schizophrenia
Date:2/24/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $224K grant from the National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product (DLP-119). The product is based on Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine for a period of 3 months.
“We are honored and thankful to receive this award which will provide valuable resources to further advance our olanzapine implant program.” said Tassos Nicolaou, President and CEO of Delpor.

Olanzapine is one of the most widely prescribed antipsychotic drugs with sales over $4 billion before its patent expired in 2011. Long-acting antipsychotics provide substantial benefits to patients and caregivers by improving medication adherence. Currently, the only available long acting formulation of olanzapine is Zyprexa® Relprevv™, a 2-4 week depot injection. Zyprexa® Relprevv™ carries the risk of post-injection delirium/sedation syndrome (PDSS), a serious condition which includes heavy sedation, coma, and delirium after injection. Patients need to be observed for at least 3 hours post-injection in a registered facility with ready access to emergency response services, and be accompanied from the facility to their destination.

Tassos Nicolaou continued: “The lack of a 3-month olanzapine formulation, creates a tremendous unmet need within this patient population. Our goal is to move beyond the 4-week limit of the current formulation while substantially improving the safety profile of the product, including eliminating the risk of PDSS, allowing for withdrawal of the medication if needed, and delivering the medication in more favorable pharmacokinetic profile.”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of biologics and antipsychotics in order to improve medication adherence, safety and convenience. The company’s lead products include 3-6 month formulations of Exenatide and Risperidone. Additional information about the company can be found at http://www.delpor.com.

About DLP-119
Delpor’s DLP-119 is a matchstick-sized titanium reservoir loaded with a unique formulation of olanzapine and implanted during a simple, 10 minute, in-office procedure with local anesthesia. The product is designed to provide a constant therapeutic dose of olanzapine each day for a total period of 3 months. Additional features include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14088705.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
2. Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Voxeleron Awarded NIH SBIR Grant for Device-independent Retinal Image Analysis Software Platform
5. IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s
6. NanoBio Awarded U.S. Patent for RSV Vaccine
7. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
8. Salk Institute awarded $25 million grant from Helmsley Charitable Trust
9. Lajollacooks4u Awarded TripAdvisor’s 2016 Certificate of Excellence
10. Worcester Polytechnic Institute Team Awarded Patent for Reprogramming Skin Cells
11. Noblis Awarded Army Contract for Support to the National Defense Center for Energy and the Environment (NDCEE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... 2017 After spending the past two years building a ... collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, ... adherence, and data collection vis a vis their members, under their ... launch of this offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... pharmaceutical and biotherapeutics development, announces the launch of the new NHS Agile ... gain kinetic binding data for a wide range of molecules, including small and ...
(Date:8/15/2017)... MA (PRWEB) , ... August 15, 2017 , ... Any ... need that has compromised these disciplines for more than half a century. Despite ... be counted. It is widely known that molecular tags developed for this purpose ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
Breaking Biology News(10 mins):